Quercetin in NAD+ Formulas: Why Is It There, and Does It Help?

Written by the Nuvirox Research Team

Short answer: quercetin is there to protect NAD+, not to boost it directly — and the logic is better than the human proof. Quercetin inhibits CD38, one of the main enzymes that breaks NAD+ down, which gives a tidy rationale for pairing it with an NAD+ precursor: build the pool up with NR, slow its breakdown with quercetin. The mechanism is real in the lab. Whether it meaningfully changes NAD+ levels in people taking precursors hasn't been proven yet.

What does quercetin actually do to NAD+?

CD38 is an NAD+-consuming enzyme whose activity rises with age and chronic inflammation — and that rising CD38 is one driver of the NAD+ decline seen in aging tissue. Foundational work showed that CD38 dictates age-related NAD+ decline and mitochondrial dysfunction. Quercetin, a plant flavonoid, can inhibit CD38. So the proposed role isn't to add NAD+ but to reduce its degradation — a "preserver" rather than a "booster."

In cell models, quercetin raised NAD+ in normal cells but produced no further rise in cells lacking CD38 — which is exactly what you'd expect if its NAD+ effect runs specifically through CD38 inhibition. That's a clean mechanistic result.

Where the evidence gets thinner

Here's the honest counterweight. Most of the CD38-inhibition data is from cells and animals, not from humans taking quercetin alongside an NAD+ precursor and showing a bigger NAD+ rise than the precursor alone. Reviews exploring NAD+ "cocktails" describe quercetin as a logical companion that may amplify a precursor's effect, while explicitly noting more studies are needed to confirm this in people. "May" and "needs confirming" are the operative words.

Quercetin also has a bioavailability problem: standard quercetin is poorly absorbed, which is why specialised forms exist. A modest dose in a blended capsule won't necessarily reach the concentrations used in mechanistic studies. None of this means quercetin is useless — it means its NAD+-preserving role should be described as plausible and supportive, not proven and central.

Quercetin's other research life

Separate from NAD+, quercetin is studied as a senolytic — a compound that may help clear senescent "zombie" cells — and as an anti-inflammatory flavonoid. The most-cited human senolytic trial actually combined dasatinib (a drug) with quercetin and reported reduced senescent cell burden in people with diabetic kidney disease. Note the combination: that trial doesn't show quercetin alone does the job, and some researchers are openly skeptical that quercetin on its own is a useful senolytic.

Why it's in NAD+ Restore

In our formula, quercetin and trans-resveratrol are included as polyphenols studied alongside NAD+ pathways for cellular health support — deliberately phrased that way because the honest evidence supports "studied alongside," not "proven to multiply your NAD+." The star of the formula, and the ingredient with the dose-response human data, is the nicotinamide riboside. Quercetin is a rational supporting cast member, described as exactly that.

If you want the evidence on the precursor that does the heavy lifting, see do NAD+ supplements actually raise NAD+, and on resveratrol specifically, NAD+ and resveratrol.

The CD38 rationale, stated carefully

The mechanistic argument for quercetin in an NAD+ formula runs through CD38, an enzyme that consumes NAD+ and whose activity rises with age — Camacho-Pereira and colleagues showed CD38 helps dictate the age-related NAD+ decline. Quercetin can inhibit CD38 in laboratory settings, so the theory is that pairing it with a precursor slows NAD+ breakdown while you supply more raw material. It's a coherent story. The honest caveat is that most of the CD38-inhibition data are preclinical, and there is no large human trial demonstrating that adding quercetin to an oral precursor produces a bigger NAD+ rise or a better outcome in people.

Quercetin's own modest human record

Quercetin isn't an inert add-in — it's a widely studied flavonoid with antioxidant and anti-inflammatory activity and a long food-source history (it's in onions, apples, capers). In the senolytic context, it's been studied alongside dasatinib in early human work by Hickson and colleagues, though that's a specific combination and dosing context, not evidence for the modest amount in a daily NAD+ capsule. The fair framing for quercetin in a formula like this is “mechanistically reasonable supporting actor,” not “proven NAD+ multiplier.”

One more practical point: the quercetin dose in a daily NAD+ formula is modest and isn't the same as the higher, often combined doses used in dedicated quercetin or senolytic research. So even where quercetin shows interesting effects in studies, you shouldn't assume the small supporting amount in a blend reproduces those results. It's there as a rational complement to the precursor, and that's the honest extent of the claim it can carry.

Frequently asked questions

Why is quercetin in my NAD+ supplement?

It can inhibit CD38, an enzyme that consumes NAD+, so the rationale is to help preserve NAD+ rather than add it. The mechanism is well shown in lab models; human confirmation is still preliminary.

Does quercetin boost NAD+ in people?

Not proven. The CD38-inhibition effect is established in cells and animals, but human trials showing quercetin amplifies a precursor's NAD+ rise are lacking.

Is quercetin a senolytic?

It's studied as one, but the main human senolytic trial paired it with the drug dasatinib. Some researchers doubt quercetin alone is effective for clearing senescent cells.

Is the quercetin dose in blends enough?

Possibly not at standard absorption. Quercetin is poorly bioavailable, so a modest blended dose may not reach the levels used in mechanistic research. It's best seen as supportive, not central.

From Nuvirox

Why we formulated NAD+ Restore

NAD+ Restore is built around 500 mg of Nicotinamide Riboside Chloride (NR) per two-capsule serving — one of the two most-researched NAD+ precursors, within the dose range used in published human trials. We pair it with 150 mg trans-resveratrol (from Japanese Knotweed) and 50 mg quercetin (from Sophora japonica), polyphenols studied alongside NAD+ pathways for cellular health support, plus 10 mg galactomannans from fenugreek to support absorption.

It ships with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

Quercetin earns its place in an NAD+ formula on a real mechanism — CD38 inhibition that could slow NAD+ breakdown — but that mechanism is mostly proven in the lab, not yet in people taking precursors. It's a sensible supporting ingredient with its own interesting research, and it should be described that way: a plausible NAD+ preserver, not the reason the formula works.

References

1. Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139. DOI: 10.1016/j.cmet.2016.05.006.
2. Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446–456. DOI: 10.1016/j.ebiom.2019.08.069.
3. Sharma A, et al. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. (review of 25 human NR trials). DOI: 10.1126/sciadv.adi4862.
4. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PMID: 29599478. DOI: 10.1038/s41467-018-03421-7.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.